All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
Dual Pricing Strategy Addresses Unique US Payer Priorities
Executive Summary
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
You may also be interested in...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Costs From ICER’s Unsupported Price Increase List Tick Back Up
Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.
Amgen Absorbs Horizon, Pitches Plans For New Rare Disease Growth Engine
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.